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Summary The potential use of tumour-specific T-lymphocytes loaded with ricin in cell targeting experiments
was investigated. Moloney-murine sarcoma virus (M-MSV)-specific T-lymphocytes, obtained in mass mixed
leucocyte-tumour cell culture (MLTC) and a M-MSV-specific cytotoxic T-lymphocyte (CTL) clone, were
incubated with 125I-labelled ricin in order to evaluate toxin uptake and release. The internalized ricin
(4.5 x 10-"7 mol and 6.5 x 10-17 mol per 102 MLTC and CTL clone cells, respectively) was released rapidly
during the first 30min following treatment, and at a constant but slower rate over the next few hours. The
cytotoxic activity of ricin-treated cells evaluated against antigen-related target cells, in a short term incubation
"Cr release assay, was unaffected during the first 30min after treatment but decreased with time over the
next few hours. However, the growth of antigen related as well as of unrelated tumour cells was strongly
inhibited by the addition of ricin-treated cells to the culture system, thus indicating that released ricin is toxic
for untreated target cells.
The in vivo localization pattern of ricin-treated radiolabelled MLTC cells was found to be comparable with
that of untreated cells 1 h after i.v. injection into syngeneic sublethally irradiated mice. After 6h, however,
more radiolabel was recovered from the liver of mice receiving ricin-treated MLTC cells.
Ricin-treated M-MSV-specific T-lymphocytes were injected i.v. into tumour bearing sublethally
irradiated mice. A temporary tumour growth inhibition (up to 6 days) was achieved following transfer of low
doses of ricin-treated MLTC or CTL clone cells (1 x 106 and 0.5 x 106, respectively). In contrast, in M-MSV
injected control mice, receiving only free toxin (from 5 to 20ng) or untreated tumour-specific effector cell
tumours grew progressively. The therapeutic effect was apparently specific since the injection of ricin-treated
alloreactive T-lymphocytes did not influence tumour growth.
These results suggest that M-MSV-specific T-lymphocytes loaded with ricin can deliver toxin to the target
tumour mass and have a transient therapeutic effect.
Lymphocytes in vitro have been shown to have specificity
both of binding to and killing of antigenic target cells
(Cerottini & Brunner, 1974). It is usually assumed that these
properties reflect the existence of a mechanism by which the
immunological apparatus can discharge its function in the
living animal. As far as cytotoxic T-lymphocytes (CTL) are
concerned, recognition of target cells and the capability to
kill them in vitro require cell-to-cell contact (Martz, 1975),
although it should be noted that there are probably a
number of indirect effects due to locally diffusible factors
that can contribute to cytotoxicity.
It is believed that one cytotoxic cell can kill one or more
target cells following contact in the appropriate milieu
(Zagury et al., 1975). This is an important finding when the
efficiency of killing is taken into account.
In a different context, the plant toxin ricin is profoundly
cytotoxic in that one molecule is thought to be sufficient to
kill a eukaryotic cell (Eiklid et al., 1980). It is also believed
that many if not all nucleated cells can internalise ricin and
recycle it to the exterior of the cell without loss of its toxicity
(McIntosh et al., 1984). By means of such toxin-carrying
capacity it is possible to extrapolate that up to five thousand
cells can be killed with the toxin associated with a single cell
(McIntosh et al., 1984).
Taking, on the one hand, the phenomenon of T-cell
cytotoxicity and, on the other, toxin carriers it was deemed
feasible to attempt to devise super-killer cells which were
capable of specificity of localisation because of their target
cell recognitive capacity and wholesale killing due to their
prior contact with appropriate amounts of ricin.
The principle involved has already been tested using
normal lymphocytes which, having been loaded with ricin,
were injected into rats (Sparshott et al., 1985). It was found
subsequently that damage to the recipient animals was most
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evident in those parts of the peripheral lymphoid system to
which the injected lymphocytes had migrated.
The aim of the present study was to ascertain whether
lymphocytes loaded with ricin could be cytotoxic in vitro
and, if they could, whether they could have any effects on
tumours in vivo which carried the target antigens. To this
end Moloney-murine sarcoma virus (M-MSV)-specific T-
lymphocytes, obtained in mass mixed leucocyte-tumour cell
culture (MLTC) and a virus-specific CTL clone were pre-
incubated with ricin prior to injection into mice carrying
M-MSV-induced tumours. Previous studies (Collavo et al.,
1980; Engers et al., 1984) have shown that T-lymphocytes
per se are highly efficient in this experimental system. The
present experiments were to determine whether T-lymphocyte
anti-tumour activity was maintained if the lymphocytes
concerned were in addition carriers of ricin.
Materials and Methods
Mice
Inbred C57BL/6 (B6) 6-8 week old mice were purchased
from the Charles River Laboratories (Calco Como, Italy).
Mice were treated with 5Gy whole body irradiation
(2.5Gymin-1, linear accelerator, 8MV, MEL, SL 75) and
injected, on the same day with M-MSV extract.
Tumour induction
M-MSV cell free extract (0.05ml), the titre of which on
3T3/FL cells was 1 x 107 focus forming unitsml-1, were
injected into the rear footpad of sublethally irradiated mice.
Three to 5 days later local tumours developed which were
measured daily using calipers.
Tumour cell lines
MBL-2, a Moloney-murine leukaemia virus (M-MuLV)-
induced T-cell lymphoma of B6 mice, was maintained by
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weekly i.p. passages of 2 x 106 cells into syngeneic mice.
P815, a chemically induced mastocytoma, was maintained by
weekly in vitro passages in complete medium. Complete
medium consisted of Dulbecco's modified essential medium
(Gibco, Glasgow, Scotland) supplemented with L-glutamine,
HEPES, 2-mercaptoethanol, antibiotics and 10% heat inacti-
vated foetal calf serum (FCS, Flow Laboratories, Opera,
Milano, Italy).
Toxin
Ricin, extracted from the seeds of Ricinus Communis and
purified to homogeneity was kindly provided by Prof. F.
Stirpe, University of Bologna, Italy.
Iodination ofRicin
Ricin (50jg) resuspended in 0.1 M sodium borate buffer,
pH 8.5, was iodinated by Bolton Hunter Reagent (Amersham
International Ltd, UK) and then passed through a column
of Sephadex G-25 to separate free 125I from the labelled
protein. Specific activity of the radioiodinated ricin was
1.2xl03cpmng-.
Loading cells with ricin
Cells (107) were incubated with 10jgml of ricin in a final
volume of 1 ml of medium serum-free at 37°C for 1 h.
Thereafter cells were washed twice with medium containing
lactose at a final concentration of 100mM, and twice with
medium supplemented with 3% FCS.
Evaluation ofuptake and release of 125I-labelled ricinfrom
cells
Cellswereincubatedwith 125I-labelledricin(15 x 106cpmml-1)
and washed four times as reported above. Labelled cells, at a
final concentration of 1 x 106mI-1, were aliquoted in 0.5ml
medium. At different time points, the radioactive ricin
released in 100I l medium of triplicate samples was measured
by gamma counter (Packard Instruments Co., Illinois) and
expressed as a percentage of the total amount of cell bound
toxin. The TCA precipitable and non-precipitable
radioactivity in the medium was also evaluated.
Cell cultures
(a) Secondary CTL were generated in vitro in an MLTC
system as previously described (Collavo et al., 1978). Briefly,
25 x 106 responder spleen cells from M-MSV tumour
regressor mice were cultured in 20ml complete medium with
1 x 106 irradiated (100 Gy) MBL-2 tumour cells for 7 days in
6% CO2 at 37°C.
(b) Alloreactive T-lymphocytes were obtained by mixing
25 x 106 B6 (H-2b) spleen cells in culture with 25 x 106 Balb/c
(H-2d) irradiated spleen cells (MLC).
(c) An M-MSV specific CTL clone was derived by micro-
manipulation of CTL and MBL-2 tumour cell conjugates
obtained from the peritoneal cavity of M-MSV immune mice
(Engers et al., 1984). The CTL clone cells were expanded
and maintained in bulk cultures following addition of 3 x 104
irradiated MBL-2 stimulator cells, 5 x 105 syngeneic feeder
layer spleen cells and 20% EL-4 supernatant as source of
interleukin-2 (IL-2).
Depletion ofLyt-2+ lymphocytes
Lymphocytes obtained in MLTC were treated with anti
Lyt-2 monoclonal antibodies and rabbit complement (C)
(Cedarlane Laboratories, Hornby, Ontario, Canada) for 1 h
at 37°C. Following this treatment -50% of the cells were
killed and the lytic activity reduced from 20 lytic units
(LU) 10-6 to 0.1 LU 10-6 recovered cells.
Cytolytic assay
Cytolytic activity was measured by incubating serial dilutions
of effector cells with 5"Cr labelled (Na25'CrO4, NEN,
Dreieich, Germany) target cells in round-bottomed microtiter
plates (Sterilin, Teddington, Middlesex, UK) as described
previously (Collavo et al., 1978). After 4h of incubation, the
plates were centrifuged, 0.1 ml supernatant removed for
counting and the percentage specific 51Cr release calculated
as follows:
100 (experimental release- spontaneous release)
(maximum release-spontaneous release)
Tumour cellproliferation assay
Cultures containing ricin-treated effector cells and 5 x 103
tumour target cells were incubated, in triplicate, at different
effector to target cell ratios in microplates containing 200jul
medium. After 48 h the cultures were pulsed with 1 pCi
3HTdR/well (NEN) and 8h later harvested on filter paper
using a cell harvester (Skatron AS, Norway). The radio-
activity was measured in a beta scintillation spectrometer
(Beckman Instruments Inc., Irvine, California). Control
cultures included tumour cells incubated in medium alone or
in medium containing free-ricin at different concentrations.
Lymphocyte injection in tumour-bearing mice
Cells treated with lOg of ricin were resuspended in medium
supplemented with 3% FCS and kept for 30min at 37°C
during which time -25% of the internalised ricin is released.
Thereafter the cells were washed, maintained in cold medium
and injected i.v. into tumour bearing mice. Control mice
were injected only with toxin or with the same dose of
untreated cells.
Assessment ofthe distribution oftransferred cells
MLTC or CTL clone cells (107) were labelled with
100jul 51Cr and at the same time loaded with 10 g of ricin.
After 1 h in a CO2 incubator, the cells were repeatedly
washed, as reported above. In one experiment, cells carrying
125I-labelled ricin, according to the protocol described
above, were used. Labelled cells (2 x 106 cells in 0.2ml
medium) were injected i.v. into tumour bearing sublethally
irradiated mice. Animals were killed either 1 or 6h following
injection. Their organs were removed and counted in a
gamma scintillation counter. Recovery from each organ was
calculated as the percentage of total radioactivity injected.
Results
Ricin uptake and release by antigen-specific T-lymphocytes
Preliminary experiments were carried out to evaluate ricin
uptake by antigen specific T-lymphocytes. MLTC cells and
CTL clones were incubated for 1 h at 37°C with 10 g of
1251-labelled ricin, then washed repeatedly in medium con-
taining 0.1 M lactose to remove toxin bound to the cell
surface. This procedure evaluates toxin internalized by pino-
cytosis (Sandvig et al., 1978). Using 1251-labelled ricin, the
amount of toxin taken up by 102 cells was calculated to be
4.5 x 10 -7mol (2.9pg) ricin when MLTC cells were used.
When cells from the CTL clone were employed the ricin
incorporation was 6.5 x 10-17mol, 4.2pg 10-2 cells. The
extent of ricin binding can differ considerably from cell type
to cell type (Sandvig et al., 1978) but in the present instance
it should be noted that the higher ricin uptake was in the
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Figure 1 Panel a: Ricin released from MLTC cells (A) or CTL
clone (A) pretreated with 1251-labelled toxin. At different time
points the release of radioactive material in the medium was
measured in triplicate samples and expressed as the percentage of
the total amount of cell bound radioactivity at time 0. Panel b:
Ricin released from CTL clone starting from 1 h of incubation.
(LI) The medium was replaced by fresh medium every hour and
the total amount of radioactive material released to the
combined medium was calculated at each time point; (-) the
medium was not changed and the radioactivity released was
measured at each time point. In all instances the coefficients of
variation were less than 10%.
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Sandvig & Olsnes (1979) observed that HeLa cells excrete
internalized ricin rapidly during the first 30min, and then at
a slower rate. Figure 1 (panel a) shows that MLTC cells
also release 1251-labelled ricin more rapidly initially than at
later times. Similar results were obtained using CTL clones.
It should be noted that less than 80% of the material
obtained in the medium is not precipitated by TCA, thus
indicating that only a small fraction of released ricin has
undergone degradation during its period of internalisation
(data not shown).
In a second series of similar experiments the external
medium of the cells was replaced every hour with an equal
quantity of fresh medium, and the radioactivity released by
MLTC cells measured as before. Under these conditions, the
rate of late toxin release was similar to that obtained in
cultures where cells were left in the same medium (Figure 1,
panel b). Moreover, at the end of the incubation MLTC
cells contained the same amount of 1251-labelled ricin,
regardless of the culture conditions in which they were
maintained.
On the basis of these experiments in vitro three things
emerge. Firstly that toxin release occurs, secondly the rate of
release is constant after the first 30min and thirdly that after
the first hour the rate of release is not affected by the
concentration of ricin in the external medium. It may be that
the concentration of ricin in the external medium does not
affect the rate of release of ricin during the first hour also,
but the experiments presented provide no information on
that score.
Cytotoxic activity ofricin-treatedantigen-specific
T-lymphocytes
Virus-specific cytotoxic cells obtained in MLTC and CTL
clones were pretreated with ricin washed repeatedly as
above, allowed to stand for a further 30min at 37°C, washed
again, and, after various time intervals, tested against rele-
vant target cells. As shown in Figure 2, 30min after these
treatments the lytic activity of the effector cells was
comparable to that of untreated controls. However, lytic
activity decreased with time over the next few hours, and at
8 h little if any cytotoxicity was detected in either cell type.
Transfer ofricin-toxicity by antigen-specific T-lymphocytes
To study whether the ricin released by cytotoxic lymphocytes
maintains its toxicity for other cells, different numbers ofricin-
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Figure 2 Cytotoxic activity of virus-specific MLTC cells and CTL clone cells at various times from ricin-treatment. MBL-2
leukaemia cells were used as target cells. Untreated effector cells( A, 0); ricin-treated effector cells (A, 0).
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Figure 3 In vitro growth of MBL-2 and P815 leukaemia cells
following addition of different doses of untreated MLTC cells,
ricin-treated MLTC cells or free ricin. Panel a: P815 plus
unltreated (A) or ricin-treated (A) MLTC cells; MBL-2 plus
unltreated (0) or ricin-treated (0) MLTC cells. Panel b: P815
(LI) or MBL-2 (-) plus free ricin.
pretreated MLTC cells were added to cultures containing
5 x 103 MBL-2 or P815 leukaemia cell lines. Cell growth
was evaluated after 48h by adding 3HTdR 8 h before culture
harvesting. Cultures containing untreated effector cells, as
well as tumour cells alone, or tumour cells and different
amounts of free toxin were used as controls. The growth of
both leukaemia cell lines was reduced by the addition of
ricin-treated cells in a manner related to the effector cell
number present in culture (Figure 3). The inhibition of
antigen-related MBL-2 leukaemia cell growth was greater
than that of antigen unrelated P815 cells. This finding is
only in part due to specific lytic activity, since untreated
MLTC cells also cause growth inhibition (Figure 3, panel
a), and, in part, to the higher susceptibility of MBL-2 cells
to the effect of free ricin (Figure 3, panel b).
Distribution ofricin-treated T-lymphocytes in vivo
Numerous studies indicate that T-lymphocytes maintained in
long term culture are trapped mainly in the lungs, and liver
of the animals in which they are transferred (Dailey et al.,
1982; Carroll et al., 1983). Sparshott et al. (1985) have shown
that ricin-treated thoracic duct lymphocytes injected into
normal animals behave as untreated cells as far as extra-
vasative capacity is concerned. We deemed it necessary to
determine the behaviour pattern of ricin-treated cultured
T-cells following injection into animals. Therefore, 2 x 106
"Cr-labelled MLTC cells were injected i.v. into sublethally
irradiated mice, which were killed I or 6h later. After 1 h no
differences in localization between ricin-treated and
untreated MLTC cells were observed (Figure 4) broadly in
accord with the more extensive results of Sparshott and her
colleagues. Most of the radioactivity was as expected found
in the lungs, and to a lower extent in the liver. Moreover,
the percentage recovery of injected radioactivity in mice
receiving ricin-treated and untreated MLTC cells was similar
(43% and 47%, respectively). After 6h, there was a decline
in radioactivity in the lungs, accompanied by an increase in
the liver; this change in the pattern of cell distribution was
more pronounced when ricin-treated MLTC cells were
transferred. Similar results were obtained using CTL clone
cells whose recovery was evaluated 6h after injection. In this
instance, the recovery was 7% in the lungs and 29% in the
liver in mice injected with ricin-treated cells and 20% in the
lung and 21% in the liver in mice receiving untreated cloned
cells (data not shown). One group of mice was also injected
with MLTC cells pre-treated with 125I-labelled ricin. In these
mice after 6h a high recovery of radiolabel in lungs and liver
(6% and 12%, respectively), comparable to that of mice
injected with 51Cr-labelled cells, was observed. In addition,
13% of the radioactivity was detected in the gastrointestinal
tract (data not shown). This is probably due to toxin freed
from cells rather than cell migration because the same
distribution is found when toxin alone is injected. These
results also indicate that free ricin is eliminated faster than
ricin interalized in the cells, since only 11% of the injected
toxin was recovered after 6h in mice receiving ricin alone,
while 48% of the radioactivity was recovered at this time
interval in mice receiving labelled cells.
Antitumour activity ofricin-treated T-lymphocyte transfer
We previously observed that the transfer of virus-specific T-
lymphocytes i.v. into syngeneic immunodepressed mice can
prevent the development of the autochthonous tumours
which otherwise develop following simultaneous injection
of M-MSV at a distant site (Collavo et al., 1980). This
tumour model was chosen to study the effect of adoptive
transfer of ricin-treated virus-specific T-lymphocytes, in view
of its high sensitivity to CTL activity and because tumour
size is readily evaluated.
Since several studies have demonstrated the antitumour
properties of ricin (Lin et al., 1970; Fodstad et al., 1976,
1977; Fodstad & Pihl, 1978), preliminary experiments were
carried out to evaluate its effect on M-MSV-induced tumour
growth. Tumour-bearing irradiated mice, receiving M-MSV
in the rear footpad 5 to 6 days previously, were injected i.v.
with various ricin doses; dose-response curves of tumour
growth in control and in ricin-treated mice show that
tumour growth slows down only when the near lethal dose
of 20 ng of ricin was injected (Figure 5); 20% of mice died in
6 to 7 days.
To evaluate the therapeutic effect of ricin-treated virus-
specific T-lymphocytes, MLTC cells were pre-incubated with
10Mg of toxin for I h at 37°C. After repeated washing in
lactose-containing medium, the cells were further incubated
at 37°C for 30min in order to eliminate ricin which is
rapidly released during this period. Sublethally irradiated
mice bearing M-MSV-induced tumours received an i.v.
inoculum of ricin-treated MLTC cells. Mice injected with M-
MSV only, or with untreated virus-specific MLTC cells, were
used as controls. Following the injection of 1 or 2 x 106
ricin-treated MLTC cells the tumour stopped growing for
several days, and then grew again at a slower rate (Figure 6).
Transfer of 2 x 106 untreated MLTC cells had no protective
effect. It should however be noted that injection of 107
untreated MLTC cells can be protective. At the cell dose
used, all mice survived for more than I month, and
eventually died following tumour enlargement. When 4 x 106
treated MLTC cells were injected all mice died within 4 to 5
days due to ricin toxicity (data not shown).
In order to evaluate whether the protective effect exerted
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Figure 4 In vivo localization of untreated (A) or ricin treated (A) MLTC cells in different organs of recipient mice at I h and 6h
after i.v. injection. Results are expressed as the percentage of injected radioactivity. Each point represents the mean (±s.d.) of 5
mice.
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Figure 5 M-MSV tumour-growth following i.v. injection of
different doses of ricin into tumour bearing mice: (A) no ricin;
(0) Sng ricin; (0) lOng ricin; (El) 20ng ricin. Broken line
represents the size of uninjected footpad. Each point represents
the mean (±s.d.) of 5 mice.
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Figure 6 M-MSV tumour-growth following i.v. transfer of
untreated or ricin-treated cells into tumour bearing mice: (A) no
cell transfer; (0) 2x 106 untreated virus-specific MLTC cells;
(-A) x 106 or 2 x 106 ricin-treated virus-specific MLTC cells;
(El) 2x 106 untreated alloreactive MLC cells; (-) 2 x 106 allo-
reactive ricin-treated MLC cells. Broken line represents the size
of uninjected footpad. Each point represents the mean (±s.d.) of
5 mice.
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by the transferred cells was specific for M-MSV antigens,
2 x 106 lymphocytes sensitized in mixed lymphocyte culture
against H-2d alloantigens were pretreated with 10/.tg of ricin
and injected i.v. into tumour bearing irradiated mice. We
observed that ricin-treated alloreactive cells did not inhibit
M-MSV tumour growth, while virus-specific MLTC cells
were efficient (Figure 6).
It was then considered that tumour growth inhibition
might result from a combined effect of CTL lytic activity
and ricin anti-tumour activity. Therefore, virus-specific
lymphocytes, obtained in MLTC, were pretreated with anti
Lyt 2 monoclonal antibodies and C to eliminate Lyt 2+
cytotoxic cells; the remaining Lyt 1+2- enriched cell
population, which lacked lytic activity against MBL-2
lymphoma cells, was pretreated with ricin and injected i.v.
into tumour bearing recipient mice. As shown in Figure 7,
the transfer of the non-cytolytic T-cell fraction conferred a
temporary protection provided that cells were pretreated
with ricin; untreated cells were again inefficient.
Recent results indicate that it is possible to cure mice of
M-MSV-induced tumours by transferring M-MSV-specific
CTL clones (Engers et al., 1984; Cerundolo et al., 1984);
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Figure 7 M-MSV tumour-growth following i.v. transfer of
untreated or ricin-treated virus-specific Lyt-2- MLTC cell
fraction into tumour bearing mice: (A) no cell transfer; (0)
2 x 106 untreated Lyt-2- MLTC cells; (0) 2 x 106 Lyt-2- ricin-
treated MLTC cells. Broken line represents to the size of
uninjected footpad. Each point represents the mean (±s.d.) of 5
mice.
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Figure 8 M-MSV tumour-growth following i.v. transfer of
untreated or ricin-treated virus-specific CTL clone cells into
tumour bearing mice: (A) no cell transfer; (0) 0.5 x 106
untreated CTL clone; (-) 0.5 x 106 ricin-treated CTL clone.
Broken line represents to the size of uninjected footpad. Each
point represents the mean (±s.d.) of 5 mice.
however, a protective effect is achieved only by using large
(2 x 107) cell doses. It was thus considered interesting to
study whether low numbers of ricin-treated cloned cells
might be effective. We observed that the injection of
0.5 x 106 cells from a M-MSV-specific CTL clone pretreated
with ricin was sufficient to inhibit tumour growth for six
days (Figure 8); transfer of higher cell doses (2 x 106) caused
rapid death of the recipient mice presumably due to ricin
toxicity (data not shown).
Discussion
The initial purpose of this work was to ascertain whether
CTL that had been exposed to ricin were still capable of
exercising their lytic activity. The answer is yes but not for
long.
Ricin is an inhibitor of ribosomal protein synthesis via the
agency of its A-chain. It is believed that the B-chain of the
toxin binds the holotoxin molecule to the surface of target
cells prior to its internalisation partly if not entirely in
coated-pit vesicles (Olsnes & Pihl, 1982). Subsequently at
least one A-chain is required to enter the cytoplasm if cell
death is to occur. It is known that the process of inter-
nalisation of holotoxin can take place in minutes and also
that when the cells concerned have been exposed to high con-
centrations of toxin, inhibition of protein synthesis can be
complete in two hours (Barbieri & Stirpe, 1982). It is about
48 h after this that the plasma membrane of the
poisoned cell disintegrates, but there is of course loss of a
number of cell functions prior to this final stage. The
relatively rapid drop off in the capacity of lyse target cells,
seen in the present study, is not surprising since CTL activity
is impaired by numerous protein synthesis inhibitors
(Henney, 1973). The small difference observed between the
cloned cytotoxic cells and the MLTC cells as far as the rate
of decline of cytotoxic potential after contact with ricin
would require confirmation before its further discussion were
worthwhile.
In vitro the difference between the killing effect of ricin
carrying cells and those cytotoxic in their own right was
evident but not large, nor perhaps could it expected to be.
The conditions in which cytotoxic assays are enacted at least
in the present study mean that the target cells are the only
ones of which the growth inhibition can be recorded. Any
ricin released from the effector cells will also have toxicity
for all cells alike in the culture. Seen in this light, any
selectivity of binding possessed by the effector cells was, in
the circumstances of the present experiments, not likely to
result in any particularly non-random distribution of the
carried toxin. In this regard, ricin released by MLTC cells
was able to inhibit proliferation of antigen-related MBL-2
and unrelated P815 leukaemic cells.
The results in vivo merit more detailed consideration.
There the tumour target cells represent a relatively small part
of the host animal into which the cytotoxic cells, ricin-
carrying or not, were injected. The specific cytotoxicity of
toxin is only that imparted to it by the effector cells. The
preliminary results in the present study show, as did the
more thorough studies of Sparshott and her colleagues
(1985), using normal lymphocytes, that ricin carrying cells
can localise in a similar manner to cells not carrying ricin at
least for a short time. It should be noted that the sites of
principal localisation in the present studies were not the sites
of tumour growth although it must be remarked that it
would be appropriate to repeat the localisation studies in
tumour-bearing animals. In parenthesis it should be noted
that attempts to demonstrate tumour localisation by injected
cytotoxic cells (e.g. Carroll et al., 1983; De Jong et al., 1985)
have only ever shown 2-4% of the cells injected at the site of
the tumour even in circumstances in which a therapeutic
effect has been observed.
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In the present study it was shown that ricin is lost from
the effector cells in vitro at a steady rate and that there is a
steady decline in the capability specifically to kill. It is
reasonable to assume that similar timing pertains in vivo. In
such circumstances the demonstration of a degree of tumour
inhibition without death of the host animal is encouraging.
Clearly the experiments could further be refined to
optimise the effects seen. The strategy to be adopted could
depend on the use of larger numbers of cells carrying smaller
burdens of ricin. Such studies will be undertaken but it is
apparent from the present experiments that the margin for
manoeuvre between enhancement of specific cytotoxicity by
ricin carrying and killing the animals due to release of toxin
in inappropriate places is small.
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